Background: Direct oral anticoagulants (DOACs) are increasingly used in place of warfarin,
but evidence about their effectiveness and safety in patients with valvular atrial fibrillation …

Background Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are at
least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among …

Abstract Background Direct oral anticoagulants (DOACs) reduce the risk of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation but may result in serious …

Background Direct oral anticoagulants (DOAC s) are noninferior to warfarin for stroke
prevention in atrial fibrillation (AF). We aimed to determine the population risk of stroke and …

Pivotal trials comparing direct oral anticoagulants (DOACs) against warfarin in patients with
atrial fibrillation (AF) predominantly involved patients with high stroke risk. This study aimed …

Purpose To compare patients with atrial fibrillation (AF) initiating direct oral anticoagulants
(DOACs) versus warfarin on clinical outcomes including stroke, systemic embolism (SE) …

Background: Oral anticoagulation (OAC) with warfarin is underused for atrial fibrillation (AF).
The availability of direct oral anticoagulants (DOACs) may improve overall OAC rates in AF …

Aims There are conflicting signals in the literature about comparative safety and
effectiveness of direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF) …

Background The management of non-valvular atrial fibrillation (AF) has evolved with the
development of direct oral anticoagulants (DOACs). However, data regarding the …

Background: Apixaban and rivaroxaban are the most commonly prescribed direct oral
anticoagulants for adults with atrial fibrillation, but head-to-head data comparing their safety …